RuiYi and arGEN-X Announce License Agreement

arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.

OrbiMed Advisors In $35 Mln Financing for OmniGuide

OmniGuide has closed a $35 million financing with OrbiMed Advisors. Cambridge, Mass.-based OmniGuide develops advanced energy surgical instruments. PRESS RELEASE OmniGuide Inc., a Cambridge, Massachusetts medical device company specializing in advanced energy surgical products, announced the closing of a $35 million non-dilutive financing with an affiliate of OrbiMed Advisors LLC. The financing structure allows OmniGuide […]

AxioMed Closes Series D Financing

AxioMed Spine Corporation, a spinal orthopedics company has closed its Series D financing, raising $5 million in two tranches from current and new investors. This funding boosts the previously announced $15 million Series D financing. Investors in the business include Siemens Venture Capital, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors. PRESS RELEASE […]

Roka Closes Series D

Roka Bioscience has secured $47.5 million in Series D financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors, New Enterprise Associates and TPG Biotech. Josh Bilenker, MD, partner at Aisling Capital, will join Roka’s board of directors. Upon completion of theround, the total amount raised since the company’s formation […]

Alexion Pharmaceuticals Buys Enobia Pharma

Alexion Pharmaceuticals Inc. will pay $610 million in cash – and as much as $470 million in future milestone-based payments – to acquire Enobia Pharma Corp. Enobia is a biopharma company developing therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders. Enobia closed a $40 million round earlier this year, and was backed by investors including OrbiMed Advisors, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners.

Acceleron Pharma Inks $30M

Cambridge, Mass.-based Acceleron Pharma Inc. has raised $30 million in financing. The company said that strategic partner Celgene contributed to the round, along with “all other existing investors.” Acceleron has raised capital from Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. The new funds will be used to expand the company’s clinical stage pipeline.

Slideshow: Where the Biotech & Device Investors Are–Q4 Edition

Lately, there’s been a whole lot of bemoaning of this and that to explain why VCs are abandoning the biotech and device space and why strategics are slowing early-stage funding. Lawmakers and regulators have made it too tough to IPO. Lawmakers and regulators have made it too tough to get anything approved at the FDA. […]

arGEN-X Inks $37M Series B

arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.

DFINE Adds $25M in Fresh Capital

DFINE Inc., a maker of minimally invasive radiofrequency targeted therapies for the treatment of vertebral pathologies, closed a $25 million. Investors include OrbiMed Advisors, Prospect Venture Partners, Split Rock Partners, BBT Fund/Apothecary Capital, Highland Capital Management and Vanguard Ventures.

Arteaus Therapeutics Inks $18M

Arteaus Therapeutics, a company developing drugs to help prevent migraines, has raised $18 million in new venture capital. Atlas Venture and OrbiMed Advisors provided the financing. Jean-Francois Formela, partner at Atlas Venture, and Thomas Schuetz from OrbiMed, serve on the company’s board. Arteaus is based in Cambridge, Mass.

Cleave Biosciences Raises $42M Series A

Cleave Biosciences has raised $42 million in venture capital to develop new treatments for cancer. The Series A round investors include U.S. Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors and Astellas Venture Management. The financing will support multiple small molecule discovery and development programs in the area of protein homeostasis, the company said.

Enobia Pharma Closes on $40M

Enobia Pharma Inc., a Montreal-based biotech company developing therapeutics for bone disorders, has closed a $40 million round. The company’s backers include OrbiMed Advisors, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners. BofA Merrill Lynch acted as the exclusive placement agent to the company.

Roka Closes $20 Mln Series C Round

Roka Bioscience has closed a $20 million Series C round of funding. OrbiMed Advisors, New Enterprise Associates, Inc., TPG Biotech and Gen-Probe Incorporated participated, according to a statement. Warren, N.J.-based Roka develops solutions using molecular technologies for the industrial markets.

Ambit Biosciences Inks $30M in D-2 Round

Ambit Biosciences, a biopharmaceutical company developing kinase inhibitors for the treatment of cancer and other conditions, has inked $30 million in new capital. Apposite Capital led the Series D-2 round, which included participation from existing investors Perseus-Soros Biopharmaceutical Fund, OrbiMed Advisors, Forward Ventures, Roche Venture Fund, MedImmune Ventures, GIMV, GrowthWorks, Genechem, Radius Ventures, NovaQuest and Horizon Technology Finance. The money will help the company continue clinical development.

Crown Bioscience Closes $28.8M Series C Financing Round

Crown Bioscience Inc. closed a Series C financing round at $28.8 million. OrbiMed Advisors Caduceus Asia Partners Fund, Argonaut Private Equity, the CID Group, IBT and CDIB Capital Investment led the round. Existing shareholders Qiming Venture Partners and CRCI also participated.Crown Bioscience plans to use proceeds to expand services in integrated cancer drug discovery and translational oncology, as well as to fund new initiatives in other therapeutic areas. Crown Bioscience is a Santa Clara, Calif.-based company involved in oncology research and development partnership and services.

AxioMed Spine Further Funded by Ohio Loan–CORRECTED

AxioMed Spine, which manufactures artificial disc replacements for medical patients, received $500,000 in the form of a loan from the state of Ohio to continue developing an artificial cervical spine disc. The company has raised $56 million to date from investors including Siemens Venture Capital GmbH, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors.

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget